Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
AssigneeCancer Research Technology Limited
InventorsSergio Quezada, Karl Peggs, Frederick Arce Vargas
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method of treating a solid tumour, wherein said method involves the use of an antibody to CD25. In particular, the antibody to CD25 is optimized for depletion of regulatory T cells (Treg) within tumours. The present invention also provides novel anti-CD25 antibodies and their combination with other anti-cancer drugs, such as immune checkpoint inhibitors, compounds that target cancer antigens or the inhibitory Fc receptor FcyRllb (CD32b).
Claims18
A method of treating a solid tumor in a human subject comprising of administering an anti-CD25 antibody and administering an immune checkpoint inhibitor to the subject, wherein the anti-CD25 antibody is a human IgG1 antibody that binds to at least one activating Fcγ receptor selected from FcγRI, FcγRIIc, and FCγRIIIa with high affinity, and depletes tumour-infiltrating regulatory T cells.
9-17. (canceled)
A pharmaceutical composition comprising an anti-CD25 antibody and an immune checkpoint inhibitor in a pharmaceutically acceptable medium.
21-29. (canceled)
Dependencies are inferred from the claim text.